We are proud of the successes of all of our former students and strive to continue to include them as part of the ICR community as they move forward in their careers.
Of those that graduated between 2010 and 2018 that completed a non-clinical research degree, 85% went directly into active scientific research roles, 88% of which were in academia and 12% in industry all over the world. Meet some of our alumni below, and read about their experience of studying at the ICR and their career journeys so far.
Completion date: PhD 2016
Dr Charlotte Pawlyn completed her PhD at The Institute of Cancer Research in 2016. She currently holds an NIHR Clinical Lectureship and continues to build her career as an academic clinician.
Completion date: PhD (non-clinical) 2014
Dr Heba Saliem completed her PhD at The Institute of Cancer Research in 2014. She was recently awarded a Sir Henry Wellcome Postdoctoral Fellowship to develop new computational methods to interpret data from large-scale imaging studies.
Dr Fiona Rowan was awarded her PhD in Biology and Chemistry at The Institute of Cancer Research in 2014. She is now an early-career academic scientist, pursuing her goal to one day lead her own research lab.
Completion date: PhD (non-clinical) 1998
Professor Dan Lloyd completed his PhD at The Institute of Cancer Research in 1998. Remaining within academia, he is now the Deputy Head of School of Biosciences at the University of Kent. His research into DNA damage, and how this relates to cancer and its treatment, underpins varied teaching, research and managerial responsibilities.
Completion date: PhD (non-clinical) 2003
Dr Ana-Teresa Maia completed her PhD at The Institute of Cancer Research in 2003. She is now the Vice-Director of the Centre for Biomedical Research at the University of Algarve.
Completion date: PhD (non-clinical) 1997
Dr Oliver Rausch completed his PhD at The Institute of Cancer Research in 1997. He is now Vice President Research & Development at Storm Therapeutics Ltd, a spin-out company from Cambridge University that is developing potential new cancer treatments.
Dr Isla Furlong completed her PhD at The Institute of Cancer Research in 1997. She now works as a patent attorney, specialising in advising start-up companies and academic institutes on biopharmaceutical patent issues.
Completion date: PhD (non-clinical) 1984
Professor Trevor McMillan was awarded a PhD in Biophysics at The Institute of Cancer Research in 1984. He is now the Vice-Chancellor of the University of Keele.
Completion date: PhD 1982 (non-clinical)
Professor John Amuasi has led a distinguished career in medical physics at the Ghana Atomic Energy Commission (GAEC) for over 40 years. In 1976, he came to the UK to carry out his MSc and PhD at the ICR.
Completion date: PhD (clinical) 2012
Dr Ingrid Slade currently holds a prestigious Wellcome Trust Research Fellowship carrying out work into ethical issues related to public health and genomic medicine. She completed her PhD in Genomic Medicine at The Institute of Cancer Research in 2012.
Completion date: PhD (clinical) 2010, Postgraduate Diploma in Oncology 2013
Dr Yap undertook a PhD in Molecular Pharmacology in the Division of Cancer Therapeutics from February 2007 to August 2010. As a Medical Oncology Specialist Registrar, he also undertook a Postgraduate Diploma in Oncology at The Institute of Cancer Research, which he completed in October 2013.
Completion date: PhD (clinical) 2009, Postgraduate Diploma in Oncology 2010
Dr Susana Banerjee completed her PhD and second year of her Postgraduate Diploma in Oncology at the ICR, and is now a Consultant Medical Oncologist at the Royal Marsden. She continues her research collaborating with the ICR and is the lead for clinical and translational trials in gynaecological cancers.
Completion date: PhD (clinical) 1995
Professor Tim Eisen completed his PhD in 1995 at the Marie Curie Research Institute in association with the Institute of Cancer Research. He is currently Head of External R&D and Strategic Alliances at AstraZeneca and Professor of Medical Oncology at the University of Cambridge. His special interests are the treatment of melanoma, lung and kidney cancers.
Our values – developed together as an organisation – make it clear how each and every one of us work to meet our mission – to make the discoveries that defeat cancer.